LONG-TERM OUTCOME OF PATIENTS WITH PAPILLARY RENAL CELL CARCINOMA

Frank Hartmann(Universität Hamburg), Marc‐Oliver Grimm(Klinik und Poliklinik für Urologie), Felix Moltzahn, R. Ackermann(University of Copenhagen), Ingmar Wolff(Universitätsmedizin Greifswald), U. Ramp(Heinrich Heine University Düsseldorf)

European Urology Supplements

April 1, 2006

10.1016/s1569-9056(06)60338-2

Cited by 0

Related Papers

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

|The Lancet Oncology|2017|1.8k

The Effect of Exercise Training Programs on Bone Mass: A Meta-analysis of Published Controlled Trials in Pre- and Postmenopausal Women

|Osteoporosis International|1999|594

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

|Blood|2006|465

An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer

|Nature Communications|2021|386

Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer

|Oncology Research and Treatment|2003|364